TLRY — Tilray Brands, Inc.

Tilray Brands, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: Achieved a record of $210 million, a 5% increase year-over-year.
• Net Income: Reported at $1.5 million, or $0.00 per share, compared to a net loss of $34.7 million in the prior year.
• Adjusted EBITDA: Increased to $10.2 million from $9.3 million year-over-year.
• Cash Position: Ended the quarter with $265 million in cash and digital assets.
• Debt Reduction: Reduced outstanding debt by $7.7 million, with a net debt to EBITDA ratio of 0.07 times.

2. Strategic Updates and Business Highlights

• Business Segments:
  • Cannabis: Revenue grew 5% to $64.5 million, driven by a 12% increase in adult-use sales and a 10% increase in international cannabis sales.
  • Beverage: Revenue reached $55.7 million, impacted by SKU rationalization but supported by new product launches contributing 2% to revenue.
  • Wellness: Revenue grew 3% to $15.2 million, with continued innovation in products.
  • Distribution: Revenue increased 9% to $74 million, benefiting from a stronger euro.
• Market Position: Tilray is the largest legal cannabis company in Canada and a leader in various beverage categories, including craft beer and hemp-derived products.
• Project 420: Achieved $25 million in annual savings, with ongoing efforts to optimize operations and improve profitability.

3. Forward Guidance and Outlook

• 2026 Guidance: Reaffirmed adjusted EBITDA guidance of $62 million to $72 million.
• Market Expansion: Plans to triple medical cannabis distribution in Germany and expand international beverage offerings.
• Regulatory Optimism: Anticipates positive changes in the regulatory landscape for cannabis in both Canada and the U.S., which could enhance market access and growth potential.

4. Challenges and Points of Concern

• Beverage Segment Margins: Gross margins declined due to a higher mix of lower-margin products and challenges in the craft beer market.
• Permit Delays: Ongoing issues with obtaining permits in Portugal could hinder international growth.
• Regulatory Risks: Uncertainty in the U.S. regarding cannabis rescheduling and potential changes in German legislation could impact market dynamics.
• Competitive Pressures: The Canadian market remains competitive with over 1,800 licensed producers, leading to price compression and market share challenges.

5. Notable Q&A Insights

• International Growth: Management expressed optimism about overcoming permit delays in Portugal and expanding market share in Germany through CC Pharma's distribution network.
• U.S. Market Readiness: If cannabis is rescheduled, Tilray believes it has the infrastructure to capture market share organically, but may consider acquisitions to enhance its position.
• Canadian Market Dynamics: The Canadian adult-use market is maturing, with pricing pressures but still significant growth potential due to low household penetration.
• Digital Assets Strategy: Tilray is exploring cryptocurrency investments, including Bitcoin, and plans to enable cryptocurrency payments on its platforms.

Overall, Tilray Brands, Inc. demonstrated solid financial performance in Q1 2026, with strategic initiatives aimed at expanding its market presence and improving profitability, while also navigating various challenges and uncertainties in the cannabis and beverage sectors.